Adiponectin(ADON),Leptin Expression Changes In The Clinical Research In Breast Cancer Patients

Objective: This paper aims to analyze the differences of serumadiponectin（ADPN）and leptin between patients with breast cancer andnon-neoplastic patients, and the relationship between Serum adiponectin,leptin and the rate, evolvement and metastasis of breast cancer, hoping toexplore the roles adiponectin and leptin play in breast cancer, thusdiscussing a new and comprehensive way to prevent breast cancer.Methods: To collect the age of32-74years old,42cases of newlydiagnosed breast cancer patients and36age30-64years old healthycontrol group, serum. Use the method of ELSIA to measure the levels ofadiponectin and leptin, and deal with the results with statistical analysis.Breast cancer according to the characteristics of the disease, menopause,different clinical and pathological features (lymph node metastasis,different TNM stage, tumor size and pathological grade, receptor status)were grouped. Analyze how serum adiponectin and leptin are related tothe above clinical features of patients with breast cancer.Results: The levels of serum adiponectin contained in group of femalepatients with breast cancer were strikingly lower than those of non-tumorgroup（6.09±1.46μg/ml vs8.69±1.88μg/ml，P<0.01）, in contrast, thelevels of leptin contained in group of female patients with breast cance are strikingly higher than those of non-tumor group （15.48±6.52ng／mlvs12.52±6.09ng／ml，P<0.01）. Stratified by menopause, the levels ofadiponectin and leptin in premenopausal women were significantly lowerthan that in postmenopausal women; the level of serum adiponectin andleptin in premenopausal women with breast cancer were respectivelylower and higher than that in non-tumor group. Meanwhile, the level ofserum adiponectin and leptin in postmenopausal women with breastcancer were respectively lower and higher than that in non-tumor controlgroup. The levels of adiponectin and leptin showed significant differencesin patients of different stages. The level of adiponectin in patients of stageII.III was lower than that in patients of stage （I11.72士1.47μg/ml vs8.44土2.69μg/ml vs7.18士2.71μg/ml，P＜0.01）, while no difference in thelevel of leptin（1.32±0.18ng／ml vs1.52±0.31ng／ml vs1.59±0.33ng／ml，P>0.05）. Lymph node metastasis was statistically significant to thelevel of adiponectin in patients, with no statistical significance to the levelof leptin. Tumor size, serum ADPN level is more pronounced with largertumors（>2cm）ADPN level is lower than in patients with smaller tumors（《2cm）in patients with serumADPN levels. LEP level and vice versa.The level of adiponectin was not related to the ER and PR of patients.Conclusions: The test of ADPN and Leptin can be regarded as animportant tumor markers of the diagnosis of patients with breast cancer.The levels of adiponectin and leptin in patients with breast cancer were respectively markedly lower and higher, which could be seen inpremenopausal and postmenopausal patients with breast cancer, with norelation to patients’ age, menopause, and body mass index. Also, it wasrevealed that the tumor was in high degree of malignancy in patients withbreast cancer whose levels of ADPN were lower and levels of leptin werehigher, indicating ADPN and leptin may play an important role in theoccurrence and development of breast cancer, and the measure of ADPNand leptin may be an effective way to the diagnosis of breast cancer.